Cue Biopharma
Cambridge
About Cue Biopharma
Cue Biopharma (Cue) is an immunotherapy company developing biologics engineered to selectively modulate disease-relevant T cells for the treatment of cancer and autoimmune disease. Cue biologics generate tailored immune responses in disease-relevant T cell populations by emulating the signals, or cues, delivered by the body’s antigen-presenting cells (APCs), and can potentially address any T cell-mediated disease. Through this platform approach, Cue has developed a portfolio of promising drug candidates with two lead programs currently approaching the clinic. Headquartered in Kendall Square, Cambridge, Massachusetts, Cue is led by a strong, experienced management team and scientific advisory board (SAB) with deep expertise in the design and clinical development of protein biologics, immunology, and immuno-oncology.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $98.4M
- Funding stage: IPO
- Last round: Post-IPO Equity (Dec 2025)
- Ticker: nasdaq:CUE
- Website: cuebiopharma.com
- Phone: 617-949-2680
Industries & Categories
Biopharma, Biotechnology, Health Care, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/cue-biopharma-52766 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.